CytoSorbents, Inc. Announces Start of $1M US Army Phase II SBIR Contract and Closing of Additional Funding

Published: Jun 27, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MONMOUTH JUNCTION, N.J., June 27, 2013 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, announced today that it has successfully completed negotiations and begun work on the previously announced $1 million Phase II SBIR (Small Business Innovation Research) contract in trauma and burn injury from the United States Army.

Help employers find you! Check out all the jobs and post your resume.

Back to news